Home / Fact sheets / Population fact sheet

Country fact sheet: Czechia

Population

- Total population: 10 566 332
- Female population: 5 373 556
- Male population: 5 192 776
The World Bank (2016)

Health Expenditure

- Total per capita (US$): 1 284.0
- Out-of-pocket (% of total expenditure on health): 14.8
World Health Organization (2015)

Human Development Index

- HDI: 0.878
- Category: Very high
UNDP Human Development Report (2015)

Geography

Life Expectancy at Birth

- Total population (years): 78.3
- Female population (years): 81.2
- Male population (years): 75.6
The World Bank (2016)

Cancer Burden

- Overall cancer incidence (rate per 100 000 persons per year): 296.7
- Overall cancer mortality (rate per 100 000 persons per year): 106.5
- Most common cancer site by incidence for females (rate per 100 000 persons per year): Breast (70.7)
- Most common cancer site by mortality for females (rate per 100 000 persons per year): Lung (13.4)
- Most common cancer site by incidence for males (rate per 100 000 persons per year): Prostate (88.0)
- Most common cancer site by mortality for males (rate per 100 000 persons per year): Lung (30.8)
- GLOBOCAN 2018 population fact sheet
GLOBOCAN (2018)

BREAST CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Mammography
(45-70 years / [24 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2002
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with Population-based cancer registry: PBCR exists but not linked

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: List from insurance company
Annual target for screening coverage:
Invitations to eligible population: Excluding those covered by opportunistic screening
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation (applicable only for population-based programmes): Roll-out completed
Cancer screening programme population based for selected populations:

Performance indicators

Target age and regional limitation if applicable: 50-69 years
Invitation coverage (%):
Examination coverage (%):
Participation rate (%):
Completeness of data related to screening results (%): 100.0
Completeness of data related to further assessment results (%):
Further assessment rate (%): 7.7
Further assessment participation rate (%): 100.0
Detection rate of CIS and invasive (x 1000): 5.24
Detection rate of invasive cancer (x 1000): 0.6
Positive predictive value of further assessment to detect CIS and invasive (%): 6.8
Proportion of total carcinomas which are CIS (%): 11.3
Benign surgical biopsy rate (x 1000): 0.27
More quantitative data (2013)



CERVICAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2016
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: Report (EU Report 2017)

Screening protocol

Year published/updated:
Screening test used: 1
Target age (min-max) and screening interval [months] for each test: Cytology
(15- years / [12 months] )
Triaging test used: None
"screen and treat" included in the protocol:

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2008
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry: PBCR exists but not linked

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: List from insurance company
Annual target for screening coverage:
Invitations to eligible population: Excluding those covered by opportunistic screening
Screening kit included with the invitation:
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based
Current status of implementation: Roll-out on going
Cancer screening programme population based for selected populations/regions:

Performance indicators

Target age and regional limitation if applicable: 30-59 years
Invitation coverage (%):
Examination coverage (invitation cohort) (%):
Examination coverage (tests in the index-year) (%): 55.2
Participation rate (%):
Completeness of data related to screening test results (%): 100
Completeness of data related to further assessment results (%): 30.7
Colposcopy referral rate (%): 1.2
Colposcopy participation rate (%):
Detection rate of CIN2+ (x 1000): 2.03
Detection rate of CIN3+ (x 1000): 1.44
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value of CIN3+ (x 1000):
More quantitative data (2013)



COLORECTAL CANCER SCREENING PROGRAMME

Last updated year for qualitative data: 2013
Source of data: Report (EU Report 2017)
Last updated year for quantitative data: 2013
Source of data: No source

Screening protocol

Year published/updated:
Screening test used: 2
Target age (min-max) and screening interval [months] for each test: FIT: (50- years / [24 months] )
Colonoscopy: (55- years / [120 months] )

Programme status and organization

Dedicated person/team to coordinate the programme:
Budget line for screening programme:
Documented cancer screening policy:
Nature of documentation of the policy: Official recommendation
Program introduction was preceded by a pilot:
Year program was initiated: 2000
Screening tests provided free of charge:
Diagnostic tests provided free of charge:
Treatment services provided free of charge:

Information system/Data collection

Data type collected by the programme: Individual
The information system collects data outside the program (opportunistic screening/private sector):
Cancer screening registries covering the entire country/region:
Cancer screening data is linked with population-based cancer registry: PBCR exists but not linked

Invitation to screening and further assessment

Method of identification of eligible individuals: From population data
Source of population data: List from insurance company
Annual target for screening coverage:
Invitations to eligible population: Excluding those covered by opportunistic screening
Method of invitation: letter
Screen positive individuals actively invited for further assessment:
Individuals with a precancer or cancer diagnosis actively contacted:
Program collects data on the treatment of precancer/cancers:

Programme monitoring and quality assurance (QA)

Documented standard operating procedure/policy for QA:
Responsible person/team for QA:
Documented performance indicators and their reference standards to assess the programme:
Evaluation reports are prepared and published:

Cancer Screening programme status

Nature of cancer screening programme: Population-based and non population-based
Current status of implementation (applicable only for population-based programmes): Roll-out on going
Cancer screening programme population based for selected populations:

Performance indicators

FIT gFOBT sigmoidoscopy Colonoscopy
Target age and regional limitation if applicable: 50-74 50-74
Invitation coverage (%):
Examination coverage (%): 31.4 1.7
Participation rate (%):
Completeness of data related to screening results (%): 100.0
Completeness of data related to information about attendance to colonoscopy assessment (%): 100.0
Completeness of data related to histology result (%): 100.0
Screen positivity (indication for follow-up colonoscopy) rate (%) : 7.4 4.1
Follow-up colonoscopy participation rate (%): 52.8 80.2
Completion rate follow-up colonoscopy (%): 96.4 96.4
Detection rate of adenomas (x 1000): 15.3 6.9
Detection rate of advanced adenomas (x 1000): 7.1
Detection rate of colorectal cancers (x 1000): 1.1 1.0
Positive Predictive Value of further assessment to detect adenomas (%): 39.0 20.9
Positive Predictive Value of further assessment to detect advanced adenomas (%): 18.2
Positive Predictive Value of further assessment to detect colorectal cancers (%): 3.0 3.1
More quantitative data for FIT (Male - 2013)
More quantitative data for FIT (Women - 2013)
More quantitative data for Colonoscopy (Male - 2013)
More quantitative data for Colonoscopy (Women - 2013)